BMS and 2seventy bio Report P-III Trial (KarMMa-3) Results of Abecma (idecabtagene vicleucel) for Multiple Myeloma
Shots:
- The P-III trial (KarMMa-3) evaluating Abecma vs standard combination regimens in 381 patients with r/r MM. The results showed an improvement in the 1EPs of PFS at a median follow-up of 18.6mos. with an m-PFS (13.3 vs 4.4mos.), 51% reduction in risk of disease progression or death
- The 2EPs of ORR also met statistical significance, 71% vs 41% achieved a response, CR or sCR (39% vs 5%), responses were durable with a median duration of 14.8 vs 9.7mos., clinical benefit was observed across difficult-to-treat subgroups
- The results were published in The NEJM & presented at the EBMT & EHA 2023. The therapy showed a consistent safety profile incl. no new safety signal, grade CRS (88%) with grade 3/4 (4%), grade 5 CRS event (1%) while grade 3/4 neurotoxicity was reported in 3%
Ref: Businesswire | Image: BMS
Related News:- BMS’ Abecma (idecabtagene vicleucel) Receives MHLW Approval for the Treatment of Multiple Myeloma
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
